MedPath

Prevalence of Thrombophilic Gene Polymorphism (MTHFR C677T) in COVID-19patients

Completed
Conditions
COVID 19 Associated Coagulopathy
Registration Number
NCT05679414
Lead Sponsor
Ain Shams University
Brief Summary

Aim of the study is to find the prevalence of thrombophilic gene methylene tetrahydrofolate reductase (MTHFR) gene polymorphism in a sample of COVID-19 patients, aiming at early detection of MTHFR mutant patients and guiding preventive therapy.

Detailed Description

The inflammatory component of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) creates a prothrombotic state that necessitates a thrombophylactic strategy for hospitalized patients. Such strategies are difficult to be standardized because certain individuals can have prothrombotic conditions, such as inherited thrombophilia, which predispose them to an additional coagulative risk. Whether outside the hospital or when admitted, patients with inherited thrombophilia need special anticoagulant attention. Identifying such patients, especially in susceptible populations like the Egyptian people, will aid primary providers in risk stratification for choosing the optimal anticoagulation plan. Case-control study which will be conducted on 33 patients who had been diagnosed as COVID-19 at Ain-Shams University isolation Hospitals and 13 healthy controls. Patients will be subjected to: Thorough history taking, Thorough clinical assessment,COVID-19 PCR+/- radiological data collection, Assessment of MTHFR C677T genotypes were determined by RT- PCR of 2 ml EDTA blood sample, Follow up patient for 28 days as regard development of vascular thrombotic manifestation (D. dimer, LL duplex, or CT chest with Pulmonary angiography if needed).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
46
Inclusion Criteria
  • All adult patients diagnosed as COVID -19 by RT-PCR will be included
Exclusion Criteria
  • Patients younger than 18 years old Patients on Antithrombotic treatment before COVID-19.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
development of vascular thrombotic manifestation4 weeks

Level of D. dimer, Lower Limb duplex, or CT chest with Puplomary Angiography if needed.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Ain Shams University

🇪🇬

Cairo, Egypt

Ain Shams University
🇪🇬Cairo, Egypt

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.